BGB-11417-304: A study to investigate sonrotoclax plus zanubrutinib compared with venetoclax plus acalabrutinib in adults with CLL
This trial aims to investigate the efficacy and safety of fixed-duration sonrotoclax plus zanubrutinib for the treatment of chronic lymphocytic leukaemia (CLL).
You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT07277231
Trial aim and background
The aim of this trial is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111), compared with fixed-duration of venetoclax plus acalabrutinib, in adults with previously untreated CLL.
Who can enter
Adults with previously untreated CLL might be eligible to take part in this trial.
Locations
Recruitment is taking place at Kings College Hospital.
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT07277231
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.